CAJ | 학술논문

目的：探讨食管鳞癌术后替加氟联合奥沙利铂辅助化疗对患者生存率的影响。方法：82例食管鳞癌手术病例，31例术后未进行化疗（单纯组），51例术后替加氟联合奥沙利铂辅助化疗（化疗组）。比较两组1年、3年、5年生存期。结果：单纯手术组1年、3年、5年生存情况分别为22例（70.97%）、18例（58.06%）、14例（45.16%），化疗组1年、3年、5年生存情况分别为46例（90.19%）、37例（72.55%）、25例（49.02%）。化疗组生存情况优于单纯手术组，但两组间长期生存率差异无显著性。结论：替加氟联合奥沙利铂用于术后辅助化疗虽能提高切除食管鳞癌患者的生存情况，但差异无显著性，食管癌术后辅助化疗有效方案需进一步深入研究。
목적：탐토식관린암술후체가불연합오사리박보조화료대환자생존솔적영향。방법：82례식관린암수술병례，31례술후미진행화료（단순조），51례술후체가불연합오사리박보조화료（화료조）。비교량조1년、3년、5년생존기。결과：단순수술조1년、3년、5년생존정황분별위22례（70.97%）、18례（58.06%）、14례（45.16%），화료조1년、3년、5년생존정황분별위46례（90.19%）、37례（72.55%）、25례（49.02%）。화료조생존정황우우단순수술조，단량조간장기생존솔차이무현저성。결론：체가불연합오사리박용우술후보조화료수능제고절제식관린암환자적생존정황，단차이무현저성，식관암술후보조화료유효방안수진일보심입연구。
Objective:To explore the survival rate of adjuvant chemotherapy on postoperative esophageal squamous carcinoma for tegafur combined oxaliplatin adjuvant chemotherapy.Methods:82 cases of esophageal squamous carcinoma surgery cases,31 cases were no postoperative chemotherapy group (simple group), 51 cases with postoperative for adjuvant chemotherapy with tegafur combined oxaliplatin (chemotherapy group).Compared with two groups of 1 year,3 years,5 years survival.Results:Simple surgical group 1 year, 3 years, 5 years survival condition was 22 cases(70.97%),18 cases(58.06%),14 cases(45.16%) respectively, chemotherapy group 1 year,3 years,5 years survival condition was 46 cases (90.19%), 37 cases (72.55%), 25 cases (49.02%) respectively. Chemotherapy group survival situation was better than that of pure surgery group, but there was no significant difference between the two groups patients for 3 years and 5 years.Conclusion:Tegafur combined oxaliplatin for postoperative adjuvant chemotherapy can improve survival in patients with resected esophageal squamous carcinoma, but there was no significant difference, adjuvant chemotherapy after esophagectomy for patients with effective solutions, which need further in-depth study.